Status and phase
Conditions
Treatments
About
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Other criteria also apply
Primary purpose
Allocation
Interventional model
Masking
1,468 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal